AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis
NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD
Overall AMPH gets a fundamental rating of 6 out of 10. We evaluated AMPH against 193 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
AMPH had a positive operating cash flow in the past year.
AMPH had positive earnings in each of the past 5 years.
Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
The Return On Assets of AMPH (8.71%) is better than 92.23% of its industry peers.
With an excellent Return On Equity value of 18.85%, AMPH belongs to the best of the industry, outperforming 91.71% of the companies in the same industry.
The Return On Invested Capital of AMPH (11.31%) is better than 88.08% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 14.76%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.71% | ||
| ROE | 18.85% | ||
| ROIC | 11.31% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
The Profit Margin of AMPH (19.38%) is better than 93.26% of its industry peers.
In the last couple of years the Profit Margin of AMPH has grown nicely.
AMPH has a better Operating Margin (26.65%) than 92.23% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
AMPH's Gross Margin of 50.50% is fine compared to the rest of the industry. AMPH outperforms 63.73% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.65% | ||
| PM (TTM) | 19.38% | ||
| GM | 50.5% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
AMPH has a better debt/assets ratio than last year.
2.2 Solvency
AMPH has an Altman-Z score of 2.61. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.61) is better than 68.91% of its industry peers.
The Debt to FCF ratio of AMPH is 4.02, which is a neutral value as it means it would take AMPH, 4.02 years of fcf income to pay off all of its debts.
AMPH's Debt to FCF ratio of 4.02 is amongst the best of the industry. AMPH outperforms 87.05% of its industry peers.
AMPH has a Debt/Equity ratio of 0.80. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
AMPH has a worse Debt to Equity ratio (0.80) than 69.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 4.02 | ||
| Altman-Z | 2.61 |
ROIC/WACC1.18
WACC9.62%
2.3 Liquidity
A Current Ratio of 2.95 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio of 2.95. This is comparable to the rest of the industry: AMPH outperforms 52.85% of its industry peers.
A Quick Ratio of 2.02 indicates that AMPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.02, AMPH is in line with its industry, outperforming 46.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.02 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased strongly by -13.47% in the last year.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
AMPH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.59%.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
3.2 Future
AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.50% yearly.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.23% yearly.
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y0.5%
Revenue Next Year-1.23%
Revenue Next 2Y2.1%
Revenue Next 3Y2.52%
Revenue Next 5Y4.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 8.60, the valuation of AMPH can be described as reasonable.
92.23% of the companies in the same industry are more expensive than AMPH, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.87. AMPH is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 8.19, the valuation of AMPH can be described as very reasonable.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 87.05% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.34, AMPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.6 | ||
| Fwd PE | 8.19 |
4.2 Price Multiples
92.75% of the companies in the same industry are more expensive than AMPH, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 92.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.36 | ||
| EV/EBITDA | 6.79 |
4.3 Compensation for Growth
AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.14
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
29.83
-0.38 (-1.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners72.89%
Inst Owner Change-2.87%
Ins Owners9.16%
Ins Owner Change6.71%
Market Cap1.41B
Analysts76.67
Price Target33.41 (12%)
Short Float %11.13%
Short Ratio8.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.55%
Min EPS beat(2)-4.55%
Max EPS beat(2)5.65%
EPS beat(4)2
Avg EPS beat(4)3.88%
Min EPS beat(4)-4.74%
Max EPS beat(4)19.17%
EPS beat(8)5
Avg EPS beat(8)11.41%
EPS beat(12)8
Avg EPS beat(12)16.64%
EPS beat(16)11
Avg EPS beat(16)20.36%
Revenue beat(2)0
Avg Revenue beat(2)-2.65%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.43%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-0.34%
Revenue beat(12)6
Avg Revenue beat(12)-0.04%
Revenue beat(16)9
Avg Revenue beat(16)0.9%
PT rev (1m)-0.76%
PT rev (3m)-7.09%
EPS NQ rev (1m)-2.4%
EPS NQ rev (3m)-0.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.3%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.6 | ||
| Fwd PE | 8.19 | ||
| P/S | 1.92 | ||
| P/FCF | 9.36 | ||
| P/OCF | 7.28 | ||
| P/B | 1.87 | ||
| P/tB | 8.43 | ||
| EV/EBITDA | 6.79 |
EPS(TTM)3.47
EY11.63%
EPS(NY)3.64
Fwd EY12.22%
FCF(TTM)3.19
FCFY10.68%
OCF(TTM)4.1
OCFY13.74%
SpS15.5
BVpS15.94
TBVpS3.54
PEG (NY)N/A
PEG (5Y)0.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.71% | ||
| ROE | 18.85% | ||
| ROCE | 13.64% | ||
| ROIC | 11.31% | ||
| ROICexc | 13.56% | ||
| ROICexgc | 26.64% | ||
| OM | 26.65% | ||
| PM (TTM) | 19.38% | ||
| GM | 50.5% | ||
| FCFM | 20.56% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexcg growth 3Y24.9%
ROICexcg growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score7
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | 4.02 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 73.47% | ||
| Cap/Sales | 5.88% | ||
| Interest Coverage | 7.56 | ||
| Cash Conversion | 76.31% | ||
| Profit Quality | 106.07% | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.02 | ||
| Altman-Z | 2.61 |
F-Score7
WACC9.62%
ROIC/WACC1.18
Cap/Depr(3y)86.1%
Cap/Depr(5y)106.5%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y0.5%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
Revenue Next Year-1.23%
Revenue Next 2Y2.1%
Revenue Next 3Y2.52%
Revenue Next 5Y4.23%
EBIT growth 1Y-7.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-3.45%
EBIT Next 3Y2.76%
EBIT Next 5Y5.95%
FCF growth 1Y192.27%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y145.14%
OCF growth 3Y29.62%
OCF growth 5Y38.57%